Volume 22, Number 9—September 2016
Proceedings of First Histoplasmosis in the Americas and the Caribbean Meeting, Paramaribo, Suriname, December 4–6, 2015
Suggested citation for this article
Histoplasmosis is not defined as a neglected disease, but in Latin America and the Caribbean, it is suspected that nearly 10,000 HIV-positive patients die from histoplasmosis disseminated beyond the respiratory tract yearly, placing this AIDS-defining illness among the main causes of death of HIV patients on a similar level as HIV-associated tuberculosis (1,2). During December 4–6, 2015, researchers and health professionals from 13 countries (Argentina, Brazil, Colombia, French Guiana, Guatemala, Guyana, Mexico, Panama, Surinam, Trinidad and Tobago, the United Kingdom, the United States, and Venezuela), representing organizations including the Pan American Health Organization, the US Centers for Disease Control and Prevention, the Foundation for Scientific Research of Suriname, and the Institut National de la Santé et de la Recherche Médicale, met in Paramaribo, Suriname, to define the next steps necessary to fight disseminated histoplasmosis in HIV patients (Figure).
The result of shared analysis of the situation surrounding disseminated histoplasmosis was that this disease is still rarely recognized in much of Latin America, notably among clinicians who care for HIV patients. Disseminated histoplasmosis is still often mistaken for tuberculosis and probably confounds tuberculosis statistics regarding treatment failure and mortality rates (3). All country representatives who attended the meeting concurred that this situation stems from the complexity and length of the diagnostic process of standard mycology and the absence of rapid, affordable, easy-to-use rapid diagnostic tests. Effects of the missed diagnoses are compounded by the lack of availability of liposomal amphotericin, the best treatment for disseminated histoplasmosis, for which attendees agreed the expense is much too high for most of Latin America (2). Furthermore, amphotericin B, deoxycholate, or itraconazole were sometimes unavailable in some countries.
Disseminated histoplasmosis is often diagnosed in patients in whom HIV is diagnosed very late in the course of the HIV infection (2). This finding suggests that, despite improved access to antiretroviral drugs, a large number of persons with HIV remain are undiagnosed and are at risk for disseminated histoplasmosis.
Recognizing these determinants of the current situation, the researchers and health professionals who attended the meeting agreed to launch the 80 by 20 Initiative. This initiative aims to provide rapid diagnostic tests and effective treatments for disseminated histoplasmosis to 80% of the reference hospitals in Latin America and the Caribbean by the year 2020.
New rapid antigen tests are soon to be released on the market, including in Latin America and the Caribbean areas. These new tests require urine or serum samples instead of samples requiring more invasive procedures, such as bone marrow, lymph node, and liver biopsies. The tests are based on ELISA methods or lateral flow devices and thus do not require very advanced laboratory methods and are relatively inexpensive. Additionally, the meeting participants recognized that regional distributors of these tests often considerably increase the cost and that the distribution network should be chosen with care to keep prices affordable.
Access to inexpensive diagnostic tests and encouragement for screening of immunocompromised HIV-infected patients who have signs of infection is expected to generate a large increase of data related to this problem and rapidly lead to updated clinical and therapeutic algorithms for patients with advanced HIV disease, as well as an adaptation of country-specific HIV strategic plans. Of greatest consequence, a rapid diagnostic test will lead to a reduction in mortality rates, as was shown in the conference presentations by representatives of Colombia, Guatemala, and Brazil, where Histoplasma antigen detection in urine samples led to rapid gains in patient survival. The question of negotiating low-priced liposomal amphotericin B is in need of rapid consideration because this would affect the most severely ill patients (4) and is already the standard recommendation in Europe and the United States.
The 80 by 20 Initiative stems from the coalescence of shared analyses of a widespread problem through a bottom-up mechanism. However, the implementation of this initiative also requires a top-down input by national public health agencies and international health organizations. The ever-increasing circle of concerned professionals has now reached a critical mass to make this specific goal a realistic one that would save numerous lives in a cost-effective way.
Dr. Nacher is a professor of epidemiology at Université de Guyane, director of the Centre d’Investigation Clinique Antilles Guyane (INSERM 1424), and the chairman for the HIV/AIDS Programme of French Guiana. His main research interest is epidemiology of disseminated histoplasmosis. Dr. Adenis is Deputy Chief of INSERM CIC1414 and is a
Dr. Adenis is senior researcher at the Centre d’Investigation Clinique Antilles Guyane (INSERM CIC1424), and is enrolled in the PhD program for Clinical Epidemiology at Université de Guyane. His main research interests are HIV and fungal diseases.
Funding for the conference was provided by Agence Nationale de la Recherche sur le Sida et les Hépatites, Agence Régionale de la Santé de Guyane, Centre Hospitalier de Cayenne, Fonds Européens de Développement Régional (Presage 31362), Foundation For Scientific Research Suriname, Global Action Fund for Fungal Infections, IMMY, Institut National de la Santé et de la Recherche Médicale, Laboratoire d’Excellence Centre d’Etudes de la Biodiversité Amazonienne, Ministry of Health Suriname, Université de Guyane.
- Nacher M, Adenis A, Mc Donald S, Do Socorro Mendonca Gomes M, Singh S, Lopes Lima I, Disseminated histoplasmosis in HIV-infected patients in South America: a neglected killer continues on its rampage. PLoS Negl Trop Dis. 2013;7:e2319. DOIPubMedGoogle Scholar
- Neglected Histoplasmosis in Latin America Group. Disseminated histoplasmosis in Central and South America, the invisible elephant: the lethal blind spot of international health organizations. AIDS. 2016;30:167–70. DOIPubMedGoogle Scholar
- Adenis A, Nacher M, Hanf M, Basurko C, Dufour J, Huber F, Tuberculosis and histoplasmosis among human immunodeficiency virus-infected patients: a comparative study. Am J Trop Med Hyg. 2014;90:216–23. DOIPubMedGoogle Scholar
- Johnson PC, Wheat LJ, Cloud GA, Goldman M, Lancaster D, Bamberger DM, ; U.S. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med. 2002;137:105–9. DOIPubMedGoogle Scholar
Suggested citation for this article: Nacher M, Adenis A. Proceedings of first Histoplasmosis in the Americas and the Caribbean meeting, Paramaribo, Suriname, December 4–6, 2015. Emerg Infect Dis. 2016 Sep [date cited]. http://dx.doi.org/10.3201/eid2209.160408
Table of Contents – Volume 22, Number 9—September 2016
|EID Search Options|
|Advanced Article Search – Search articles by author and/or keyword.|
|Articles by Country Search – Search articles by the topic country.|
|Article Type Search – Search articles by article type and issue.|
Please use the form below to submit correspondence to the authors or contact them at the following address:
Addresses for correspondence: Mathieu Nacher; ; Antoine Adenis; ; Centre d'Investigation Clinique Antilles Guyane, Inserm CIC1424, Centre Hospitalier de Cayenne, Av. des flamboyants, BP 6006, 97306 Cayenne CEDEX